RYTM (Rhythm Pharmaceuticals) Pre-Tax Income : $-258.3 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Rhythm Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was $-44.0 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-258.3 Mil. Rhythm Pharmaceuticals's pretax margin was -132.28%.

During the past 9 years, Rhythm Pharmaceuticals's highest Pretax Margin was -229.52%. The lowest was -2207.10%. And the median was -766.22%.

Rhythm Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Rhythm Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals Pre-Tax Income Chart

Rhythm Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-140.73

-134.00

-69.61

-181.12

-184.11

Rhythm Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial															-43.80	-41.44	-141.07	-31.78	-43.99

Competitive Comparison of Rhythm Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Rhythm Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rhythm Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rhythm Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Rhythm Pharmaceuticals's Pre-Tax Income falls into.

Rhythm Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Rhythm Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-184.357	+	0.19	+	-13.892	+	13.945	+	0
	=	-184.1

Rhythm Pharmaceuticals's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-43.885	+	1.088	+	-5.242	+	4.054	+	-7.105427357601E-15
	=	-44.0

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-258.3 Mil.

Rhythm Pharmaceuticals (NAS:RYTM) Pre-Tax Income Explanation

Rhythm Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-43.985	/	33.251
	=	-132.28%

During the past 9 years, Rhythm Pharmaceuticals's highest Pretax Margin was -229.52%. The lowest was -2207.10%. And the median was -766.22%.

Rhythm Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (NAS:RYTM) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

RYTM:Mexico 1RV:Germany

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

http://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Executives

Joseph Shulman	officer: Chief Technical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Jennifer Chien	officer: EVP, Head of North America	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Pamela J. Cramer	officer: Chief Human Resources Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Jennifer L Good	director	15 GREAT RING ROAD, SANDY HOOK CT 06482
Lynn A. Tetrault	director	12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Christopher Paul German	officer: Corporate Controller & CAO	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Hunter C Smith	officer: CFO and Treasurer	C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820
Yann Mazabraud	officer: EVP, Head of International	C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510
David P Meeker	director	C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810
William T. Roberts	officer: Chief Accounting Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Linda Shapiro Manning	officer: Chief Medical Officer	C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Camille L Bedrosian	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nithya Desikan	officer: Chief Commercial Officer	82 BAY STATE ROAD, BELMONT MA 02478